Liposarcoma Clinical Trials 2023

Browse 39 Liposarcoma Medical Studies Across 128 Cities

6 Phase 3 Trial · 394 Liposarcoma Clinics

Reviewed by Michael Gill, B. Sc.
10 Liposarcoma Clinical Trials Near Me
Top Hospitals for Liposarcoma Clinical Trials
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
9Active Trials
12All Time Trials for Liposarcoma
2010First Liposarcoma Trial
Image of Dana-Farber Cancer Institute in Massachusetts.
Dana-Farber Cancer Institute
Boston
6Active Trials
14All Time Trials for Liposarcoma
1997First Liposarcoma Trial
Image of MD Anderson Cancer Center in Texas.
MD Anderson Cancer Center
Houston
5Active Trials
6All Time Trials for Liposarcoma
2012First Liposarcoma Trial
Image of Moffitt Cancer Center in Florida.
Moffitt Cancer Center
Tampa
5Active Trials
6All Time Trials for Liposarcoma
2014First Liposarcoma Trial
Image of Dana Farber Cancer Institute in Massachusetts.
Dana Farber Cancer Institute
Boston
5Active Trials
5All Time Trials for Liposarcoma
2015First Liposarcoma Trial
Top Cities for Liposarcoma Clinical Trials
Image of Boston in Massachusetts.
Boston
22Active Trials
Dana-Farber Cancer InstituteTop Active Site
Image of New York in New York.
New York
21Active Trials
Memorial Sloan Kettering Cancer CenterTop Active Site
Liposarcoma Clinical Trials by Phase of Trial
Phase < 1 Liposarcoma Clinical Trials
1Active Liposarcoma Clinical Trials
1Number of Unique Treatments
2Number of Active Locations
Liposarcoma Clinical Trials by Age Group
< 65 Liposarcoma Clinical Trials
3Active Liposarcoma Clinical Trials
Most Recent Liposarcoma Clinical TrialsTop Treatments for Liposarcoma Clinical Trials
Treatment Name
Active Liposarcoma Clinical Trials
All Time Trials for Liposarcoma
First Recorded Liposarcoma Trial
Radiation Therapy
2
5
2006
Seclidemstat
2
2
2018
Abemaciclib
2
2
2016
Single Agent Therapy Dose Expansion
1
1
2023
CATCH T cells
1
1
2021
Recently Completed Studies with FDA Approved Treatments for Liposarcoma
Treatment
Year
Sponsor
Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
2018
M.D. Anderson Cancer Center
Pharmacological Study
2017
OHSU Knight Cancer Institute
letetresgene autoleucel (GSK3377794)
2016
GlaxoSmithKline
Dexrazoxane
2016
Washington University School of Medicine

What are Liposarcoma Clinical Trials?

Liposarcoma refers to cancer in the fatty tissue. This particular cancer causes the growth of tumors in various regions of the body, including the abdomen and thigh. Although rare, Liposarcoma is one of the most dangerous cancers as it is malignant, which means that this cancer can spread.

This cancer spreads to other body areas, and once it invades the vital organs, a patient requires immediate treatment.

While the cause of Liposarcoma is not verified, experts believe that the most significant contributors to the disease are a genetic component of mutation that is accelerated by coming into contact with certain mutagens, especially radiation. Research shows that the disease occurs due to a mutation in chromosome 12q13-15 that amplifies the MDM2 and CDK4 genes.

Liposarcoma clinical trials refer to the research being done to study and evaluate the disease, the diagnosis, treatment, and prevention methods.

Why is Liposarcoma Being Studied Through Clinical Trials?

Liposarcoma is malignant cancer that affects around 2000 Americans yearly and makes up one percent of all global cancers. The cancer is not as dangerous if localized, with a mortality rate of 10% within five years of diagnosis. However, if the cancer spreads or reaches an advanced stage, the five-year mortality rate increases to 44%.

Research shows that soft tissue sarcomas likely metastasize in around 50% of patients. Hence, with a high probability rate of developing metastasized or advanced-stage liposarcoma, the need to find a solution to the problem is vital.

Liposarcoma is primarily present in people aged 50 or above. While there's a genetic component to the condition, several mutagenic factors can influence the development of the cancer.

Therefore, researchers around the globe are carrying out liposarcoma clinical trials to study the causes and effects of the disease and evaluate the efficacy of new modes of treatment.

What Are The Types of Treatments Available for Liposarcoma?

Different approaches to treating Liposarcoma depend on the type and stage of liposarcoma cancer. The treatment can also vary, depending on whether the cancer is localized or has metastasized. Research done by Candace L Haddox and Richard Riedel assesses the efficacy and potentiality of different treatments, including:

  • Surgical: Involve removing the tumor surrounding the healthy fat tissue.
  • Radiation: Involve treating the tumor using high doses of X-ray radiation after surgery to reduce risks of remission.
  • Cytotoxic Chemotherapy: Involve using drugs that kill cancer cells, either administered through an injection or as a pill.

What Are Some Recent Breakthrough Clinical Trials For Liposarcoma

In recent years, Liposarcoma has identified several novel therapeutical methods to treat the cancer. In contrast to the previously existing therapies, these treatment methods target the cancer as researchers designed these trials after thoroughly assessing the inherent biology behind the disease. Some of the most recent breakthrough clinical trials for Liposarcoma include:

2018: a liposarcoma clinical trial conducted by Janssen Research and Development to assess the efficacy of marine-derived compounds Trabectedin in treating advanced-stage liposarcoma. In the US, these studies are currently in phase III.

2020: a clinical trial to study the efficacy of immunotherapy Pembrolizumab to stimulate the immune system to fight cancer cells. The study is being conducted by the Sarcoma Alliance for Research and is currently in phase II.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 11th, 2021

Last Reviewed: September 16th, 2023

References1 Vatner R, James CD, Sathiaseelan V, Bondra KM, Kalapurakal JA, Houghton PJ. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges. Pediatr Blood Cancer. 2021 May;68 Suppl 2:e28439. doi: 10.1002/pbc.28439. Epub 2020 Aug 22. https://pubmed.ncbi.nlm.nih.gov/328273532 Vatner R, James CD, Sathiaseelan V, Bondra KM, Kalapurakal JA, Houghton PJ. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges. Pediatr Blood Cancer. 2021 May;68 Suppl 2:e28439. doi: 10.1002/pbc.28439. Epub 2020 Aug 22. Review. https://pubmed.ncbi.nlm.nih.gov/328273533 Goff PH, Riolobos L, LaFleur BJ, Spraker MB, Seo YD, Smythe KS, Campbell JS, Pierce RH, Zhang Y, He Q, Kim EY, Schaub SK, Kane GM, Mantilla JG, Chen EY, Ricciotti R, Thompson MJ, Cranmer LD, Wagner MJ, Loggers ET, Jones RL, Murphy E, Blumenschein WM, McClanahan TK, Earls J, Flanagan KC, LaFranzo NA, Kim TS, Pollack SM. Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells. Clin Cancer Res. 2022 Apr 14;28(8):1701-1711. doi: 10.1158/1078-0432.CCR-21-4239. https://pubmed.ncbi.nlm.nih.gov/351153064 Sanderson JP, Crowley DJ, Wiedermann GE, Quinn LL, Crossland KL, Tunbridge HM, Cornforth TV, Barnes CS, Ahmed T, Howe K, Saini M, Abbott RJ, Anderson VE, Tavano B, Maroto M, Gerry AB. Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy. Oncoimmunology. 2019 Nov 24;9(1):1682381. doi: 10.1080/2162402X.2019.1682381. eCollection 2020. https://pubmed.ncbi.nlm.nih.gov/320022905 Schroeder BA, Black RG, Spadinger S, Zhang S, Kohli K, Cao J, Mantilla JG, Conrad EU, Riddell SR, Jones RL, Yee C, Pollack SM. Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy. J Immunother Cancer. 2020 Apr;8(1):e000247. doi: 10.1136/jitc-2019-000247. https://pubmed.ncbi.nlm.nih.gov/322691426 Schroeder BA, Black RG, Spadinger S, Zhang S, Kohli K, Cao J, Mantilla JG, Conrad EU, Riddell SR, Jones RL, Yee C, Pollack SM. Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy. J Immunother Cancer. 2020 Apr;8(1). pii: e000247. doi: 10.1136/jitc-2019-000247. https://pubmed.ncbi.nlm.nih.gov/322691427 Kim H, Nguyen NP, Turner K, Wu S, Gujar AD, Luebeck J, Liu J, Deshpande V, Rajkumar U, Namburi S, Amin SB, Yi E, Menghi F, Schulte JH, Henssen AG, Chang HY, Beck CR, Mischel PS, Bafna V, Verhaak RGW. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat Genet. 2020 Sep;52(9):891-897. doi: 10.1038/s41588-020-0678-2. Epub 2020 Aug 17. https://pubmed.ncbi.nlm.nih.gov/328079878 Tobias A, O'brien MP, Agulnik M. Olaratumab for advanced soft tissue sarcoma. Expert Rev Clin Pharmacol. 2017 Jul;10(7):699-705. doi: 10.1080/17512433.2017.1324295. Epub 2017 May 5. Review. https://pubmed.ncbi.nlm.nih.gov/284474759 Avutu V, Weiss AR, Reed DR, Ahmed SK, Allen-Rhoades WA, Chen YE, Davis LE, Eaton BR, Hawkins DS, Indelicato DJ, Patel SR, Randall RL, Reinke DK, Riedel RF, Scharschmidt TJ, Thornton KA, Wang D, Janeway KA, Kopp LM. Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321. J Adolesc Young Adult Oncol. 2021 Sep 9. doi: 10.1089/jayao.2021.0103. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/3451554410 Hickman TL, Choi E, Whiteman KR, Muralidharan S, Pai T, Johnson T, Parikh A, Friedman T, Gilbert M, Shen B, Barron L, McGinness KE, Ettenberg SA, Motz GT, Weiss GJ, Jensen-Smith A. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity. PLoS One. 2022 May 4;17(5):e0266980. doi: 10.1371/journal.pone.0266980. eCollection 2022. https://pubmed.ncbi.nlm.nih.gov/35507536